Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi to pay Lexicon for terminated partnership

Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.

Read More »

Vertex Branches Into Diabetes, Acquiring Semma for $950 Million

Vertex Pharmaceuticals announced a deal to buy Semma Therapeutics, which focuses on using stem cell-derived human islets as a possible cure for type 1 diabetes.

Read More »

Lexicon Posts Positive 52-Week Pooled Zynquista Data in Type 1 Diabetes

Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.

Read More »

Sanofi ends partnership with Lexicon to develop diabetes drug

French drugmaker Sanofi SA terminated a partnership with Lexicon Pharmaceuticals Inc. to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

Read More »

FDA Approves First Needle-Free Glucagon to Treat Severe Hypoglycemia

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

Read More »

AstraZeneca’s Farxiga fails to receive U.S. approval for type 1 diabetes

The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.

Read More »

Experimental drug delays type 1 diabetes onset in mid-stage trial

In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.

Read More »

Zealand Pharma’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.

Read More »

EU approves AstraZeneca’s drug for adjunct use in Type 1 diabetes

British drugmaker AstraZeneca Plc said on Monday the European Commission approved the company’s diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.

Read More »

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc. intended for use with insulin in patients with type 1 diabetes, the companies said.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom